These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29890569)

  • 1. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease.
    Sayari S; Neishaboori H; Jameshorani M
    Clin Mol Hepatol; 2018 Sep; 24(3):331-338. PubMed ID: 29890569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD.
    Hadi A; Mohammadi H; Miraghajani M; Ghaedi E
    Crit Rev Food Sci Nutr; 2019; 59(15):2494-2505. PubMed ID: 29584449
    [No Abstract]   [Full Text] [Related]  

  • 3. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term synbiotic supplementation in addition to lifestyle changes in children with obesity-related non-alcoholic fatty liver disease.
    Çakır M; Aksel İşbilen A; Eyüpoğlu İ; Sağ E; Örem A; Mazlum Şen T; Kaklıkkaya N; Kaya G
    Turk J Gastroenterol; 2017 Sep; 28(5):377-383. PubMed ID: 28797988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
    Wang X; Zhao B; Sun H; You H; Qu S
    Front Endocrinol (Lausanne); 2022; 13():866189. PubMed ID: 36072931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
    Cho YK
    Clin Mol Hepatol; 2018 Sep; 24(3):299-301. PubMed ID: 30196651
    [No Abstract]   [Full Text] [Related]  

  • 7. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.
    Khan MY; Mihali AB; Rawala MS; Aslam A; Siddiqui WJ
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):703-715. PubMed ID: 31009401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study.
    Eslamparast T; Poustchi H; Zamani F; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Am J Clin Nutr; 2014 Mar; 99(3):535-42. PubMed ID: 24401715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sour tea supplementation on liver enzymes, lipid profile, blood pressure, and antioxidant status in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled clinical trial.
    Izadi F; Farrokhzad A; Tamizifar B; Tarrahi MJ; Entezari MH
    Phytother Res; 2021 Jan; 35(1):477-485. PubMed ID: 32909326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
    Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
    World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats.
    Akaslan SB; Degertekin CK; Yilmaz G; Cakir N; Arslan M; Toruner FB
    Metab Syndr Relat Disord; 2013 Aug; 11(4):243-50. PubMed ID: 23544853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females.
    Wang L; Guo J; Lu J
    Oncotarget; 2016 Jun; 7(24):35632-35642. PubMed ID: 27248665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial.
    Darvish Damavandi R; Shidfar F; Najafi M; Janani L; Masoodi M; Akbari-Fakhrabadi M; Dehnad A
    Phytother Res; 2021 Jun; 35(6):3145-3156. PubMed ID: 33880813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.
    Askari F; Rashidkhani B; Hekmatdoost A
    Nutr Res; 2014 Feb; 34(2):143-8. PubMed ID: 24461315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.
    Kanchanasurakit S; Kositamongkol C; Lanoi K; Nunta M; Saetuan T; Chaiyakunapruk N; Saokaew S; Phisalprapa P
    Front Nutr; 2022; 9():880014. PubMed ID: 35669067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Mirhafez SR; Farimani AR; Dehhabe M; Bidkhori M; Hariri M; Ghouchani BF; Abdollahi F
    J Gastrointestin Liver Dis; 2019 Jun; 28():183-189. PubMed ID: 31204416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: A randomized double blind placebo controlled clinical trial.
    Nabhani Z; Hezaveh SJG; Razmpoosh E; Asghari-Jafarabadi M; Gargari BP
    Diabetes Res Clin Pract; 2018 Apr; 138():149-157. PubMed ID: 29432772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Childs CE; Del Fabbro S; Bilson J; Moyses HE; Clough GF; Sethi JK; Patel J; Wright M; Breen DJ; Peebles C; Darekar A; Aspinall R; Fowell AJ; Dowman JK; Nobili V; Targher G; Delzenne NM; Bindels LB; Calder PC; Byrne CD
    Gastroenterology; 2020 May; 158(6):1597-1610.e7. PubMed ID: 31987796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effects of Synbiotic Supplementation on Body Mass Index, Metabolic and Inflammatory Biomarkers, and Appetite in Patients with Metabolic Syndrome: A Triple-Blind Randomized Controlled Trial.
    Rabiei S; Hedayati M; Rashidkhani B; Saadat N; Shakerhossini R
    J Diet Suppl; 2019; 16(3):294-306. PubMed ID: 29672196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.